Shenouda With me on today's call are Relmada Therapeutics, Inc.'s CEO, Dr. Sergio Traversa, who will briefly provide a summary of recent business highlights; Dr. Raj S. Pruthi, Relmada Therapeutics, ...

Thank you, Chinwe, and hello, everyone. On today's call, I will review our fourth quarter and full-year 2025 performance and discuss the substantial progress we have made over the past two years. With ...

Thank you, and welcome to Curis' Fourth Quarter 2025 Business Update Call. Before we begin, I'd like to encourage ...

My initial comments will briefly highlight our fourth quarter and full-year 2025 results, along with the steps we are taking ...

Cash Position -- Cash and equivalents as of December 31, 2025, plus $20.2 million initial proceeds from a January 2026 PIPE and potential further $20.2 million upon milestone, are expected to fund ...

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2025 Earnings Call Transcript March 17, 2026 Trevi Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.09657.

Longeveron Inc. (NASDAQ:LGVN) Q4 2025 Earnings Call Transcript March 17, 2026 Longeveron Inc. beats earnings expectations.

The younger brother of a woman who alleges she was sexually abused by seven members of her family told gardai the allegations about him were a “joke”, a Central Criminal Court trial has heard.

A court ruling may allow taxpayers to claim refunds on IRS late fees from 2019–2022 pandemic filings, but claims must be submitted by July 10.